Compare IDEXX Laboratories, Inc. (IDXX) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tilray Brands Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Tilray Brands Inc trades at $4.69 (market cap $649.42M). The key difference: IDEXX Laboratories, Inc. is far larger — about 71.2× Tilray Brands Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| IDXX | TLRY | |
|---|---|---|
Market Cap | $46.22B | $649.42M |
Sector | Health | Health |
52-Week High | $766.68 | $21.00 |
52-Week Low | $526.44 | $3.88 |
Enterprise Value | $47.12B | $816.55M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
TLRY trades at $4.68, up 5.88% today, amid bullish technical signals and news-driven momentum. The company reported record fiscal 2026 revenue of $915 million but posted a net loss of $121 million, with profitability challenges persisting. Recent developments include new product launches and partnerships, while analyst sentiment remains mixed with a majority hold rating.
Outlook hinges on revenue growth and margin improvement, but risks include sustained losses, high debt, and competitive pressures. The stock offers speculative appeal if execution improves, yet volatility and dilution concerns warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
